Carl Icahn went public Tuesday morning, August 7, with his campaign against Cigna’s US$54 billion plan to buy Express Scripts. The billionaire activist investor sent an open letter urging fellow Cigna shareholders to vote against the deal.
Icahn called the deal a “$60 billion folly” carrying a “ridiculous” price tag, according to a draft seen by The Wall Street Journal.
CPI previously reported that Mr. Icahn bought a sizable Cigna stake, plans to vote against the health insurer’s proposed purchase of the pharmacy-benefit manager, and was considering publicly airing his concerns to persuade other shareholders to do the same.
His concerns include competitive risk from Amazon and indications from the Trump administration that it could limit the manufacturer rebates pharmacy-benefit managers get.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
UK Regulator Investigates Tech Giants’ AI Partnerships Amid Competition Concerns
Apr 24, 2024 by
CPI
TikTok CEO Confident of Overcoming US Ban: ‘We’re Here to Stay’
Apr 24, 2024 by
CPI
EU Conducts First-Ever Raids on a Company Under Foreign Subsidies Regulation
Apr 23, 2024 by
CPI
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI